Ainos, Inc. reported that its open‑label, multi‑dose study of VELDONA, a low‑dose oral interferon‑alpha formulation, achieved statistically significant interim efficacy in treating feline chronic gingivostomatitis (FCGS). The announcement was made on February 17, 2026, after the company completed an interim analysis of the first six treated cats.
The trial enrolled 12 client‑owned cats across two dosing cohorts—6,000 IU and 12,000 IU—administered three times per week for six weeks. At week 6, all six cats in the interim cohort showed lower oral inflammation scores, with a mean improvement of approximately 38 %. Two‑thirds of the subjects (66.7 %) achieved a clinically meaningful improvement of at least 30 %, and the difference from baseline was statistically significant (Wilcoxon signed‑rank test, p < 0.05). A week‑14 follow‑up indicated a further increase in mean improvement to roughly 45 %, and no serious adverse events were reported, underscoring VELDONA’s favorable tolerability profile.
These interim results represent a pivotal milestone for Ainos’ veterinary pipeline, positioning VELDONA as a potential steroid‑free therapeutic for a disease that currently lacks durable long‑term options. The findings also reinforce the company’s broader VELDONA program, which includes human indications such as oral warts in HIV‑positive patients and Sjögren’s syndrome, and highlight the dual‑platform strategy that blends AI‑driven SmellTech with biotech innovation.
The announcement underscores Ainos’ capacity to advance a low‑dose interferon platform across species, while the potential to tap into the projected $13 billion global pet dental health market could materially expand the company’s commercial footprint if regulatory approval is achieved.
Overall, the interim efficacy data strengthen Ainos’ position in the veterinary therapeutics space and provide a foundation for future development and potential market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.